<DOC>
	<DOCNO>NCT00373048</DOCNO>
	<brief_summary>This randomize placebo control trial . Malaria chemoprophylaxis mefloquine asymptomatic HIV-infected adult live malaria endemic region Luanshya , Zambia compare placebo control group follow 18 month .</brief_summary>
	<brief_title>Mefloquine Prophylaxis HIV-1 Individuals : Randomized Placebo-controlled Trial</brief_title>
	<detailed_description>In Zambia prompt treatment malaria case mainstay malaria control ; antimalarial chemoprophylaxis currently recommend general use use placebo comparator study justify . We analyse safety efficacy mefloquine , malaria AIDS relate parameter predefined time point , verify intervention could produce slow decrease CD4 count compare passive case management malaria . This randomized placebo control trial . Malaria chemoprophylaxis mefloquine asymptomatic HIV-infected adult live malaria endemic region Luanshya , Zambia compare placebo control group follow 18 month . Specific design study take account possible confounding parameter ( interaction ) need measure impact malaria control HIV endemic environment . In particular , question answer malaria control impact disease progression HIV . The possible impact intervention morbidity mortality take account parameter might major public health impact . This might use antiretroviral drug , incidence clinical ( eventually severe ) malaria spread antimalarial resistance immune compromise HIV patient ( without antimalarial treatment ) . Studies alternative strategy contribute ( next antiretrovirals ) control prevention HIV pandemic equally important urgently need . The need design strategies critical give high incidence malaria HIV country Sub Saharan Africa Zambia serious impact survival socio-economic situation . Moreover , cost-benefit analysis might show alternative strategy major impact field less technical , financial social constraint strategy recommend far . All HIVP patient treat opportunistic infection ( OI ) receive antiretroviral drug follow National guideline Management Care Patients HIV/AIDS ( also occur study period ) . At time need cotrimoxazole prevention or/and receive antiretrovirals would reach study endpoint exclude trial though follow continue .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Permanent resident Luanshya district Males non pregnant adult 18 50 year old . Having CD4 cell count least 350 perÂµL enrolment HIV serostatus determine VCT health center . No obvious underlie disease time enrolment Signed informed consent HIV stage III IV follow WHO classification ( see attach document regard policy Zambia ) Evidence underlie chronic disease ( cardiac , renal , hepatic , malnutrition , TB ) . Intent move study catchment area study period History allergy MQ ( related drug ) sulfa drug Chorionic gonadotrophic hormone urine obvious pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HIV-1 malaria Clinical Trial</keyword>
</DOC>